Establishment of cancer/testis antigen profiling based on clinicopathological characteristics in resected pathological stage III non-small cell lung cancer.
Establishment of cancer/testis antigen profiling based on clinicopathological characteristics in resected pathological stage III non-small cell lung cancer.
复制标题
基于切除病理III期非小细胞肺癌临床病理特征的癌症/睾丸抗原分析的建立
DOI：
10.2147/cmar.s164043
复制
发表时间：
2018
影响因子：
3.3
通讯作者：
Yu Y
中科院分区：
文献类型：
--
作者：
Jin S;Cao S;Grigorev A;Li J;Meng Q;Wang C;Feng M;Hu J;Jiang F;Yu Y
背景在以前的研究中发现，肿瘤/睾丸抗原（CTA）表达是高度异质性的。我们的目的是在切除的III期非小细胞肺癌（NSCLC）中建立精确的CTA分析，并证明覆盖最广泛NSCLC病例的最佳CTA组合。材料与方法对200例Ⅲ期NSCLC手术切除标本中10种CTA的表达进行蛋白水平检测。使用分层聚类和python编程语言分析来证明CTA表达和覆盖率。结果MAGEA 1、MAGEA 10和KK-LC-1在胃癌中的表达率分别为60.0%、50.0%和47.5%。CTA的表达是组织学依赖性的，同时表达是常见的。最佳2、3和4次CTA组合分别覆盖总病例的72.0%、76.5%和79.5%。基于可变临床病理特征的分层分析在具有男性、阳性吸烟史和腺癌特征的患者中仅使用2种CTA组合实现了92.3%的最大覆盖率，而当评估10种CTA时，覆盖率为85.0%。根据亚组分析，选择的CTA表达与预后相关。CTA表达与表皮生长因子受体突变状态无显著差异。结论根据10种CTA表达建立了III期NSCLC患者个体化CTA表达谱。在计算机编程语言的帮助下，通过使用基于性别、吸烟史和组织学的最少CTA组合来达到最大CTA表达覆盖率的目标。这些结果对CTA特异性T细胞免疫治疗的进一步研究具有重要意义。
Background Cancer/testis antigen (CTA) expression was found to be highly heterogeneous in previous studies. We aimed to establish a precision CTA profiling in resected stage III non-small cell lung cancer (NSCLC) and demonstrate the best CTA combination covering the widest range of NSCLC cases. Materials and methods The expression of 10 CTAs was evaluated in 200 resected stage III NSCLC tissue specimens at protein level. Hierarchical clustering and python programming language analyses was used to demonstrate CTA expression and coverage. Results The most commonly expressed CTAs for total cases were MAGEA1 (60.0%), MAGEA10 (50.0%), and KK-LC-1 (47.5%). CTA expression was histology dependent, and concurrent expression was common. The best 2, 3, and 4 CTA combination covered 72.0%, 76.5%, and 79.5% of total cases, respectively. Stratified analysis based on variable clinicopathological characteristics achieved the maximum coverage of 92.3% with only 2 CTA combination in patients with features of male sex, positive smoking history, and adenocarcinoma, compared with a 85.0% coverage when 10 CTAs were assessed. Selected CTA expression was correlated with prognosis based on subgroup analysis. No significant difference was found between CTA expression and epidermal growth factor receptor mutant status. Conclusion We established an individualized CTA profiling in resected stage III NSCLC based on 10 CTA expression. With the help of computer programming language, the goal of the maximum CTA expression coverage was reached by using the least CTA combination based on sex, smoking history, and histology. These results were significant for the further study of CTA-specific T-cell immunotherapy.